{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:28:37Z","timestamp":1784690917337,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neurot.2026.e00880","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:11:49Z","timestamp":1773353509000},"page":"e00880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal multi-omics profiling of spinal muscular atrophy"],"prefix":"10.1016","volume":"23","author":[{"given":"Ivana","family":"Dabaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Hai Yen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Lagrue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Ducatez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Allouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Ausseil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Seferian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gomez - Garcia de la Banda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Benezit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Phelep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondher","family":"Chouchane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Chapart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Quijano Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdellah","family":"Tebani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumeya","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neurot.2026.e00880_bib1","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.neurot.2026.e00880_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fneur.2020.00783","article-title":"Editorial: spinal muscular atrophy: evolutions and revolutions of modern therapy","volume":"11","author":"Finkel","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e00880_bib3","first-page":"39","article-title":"Advances in newborn screening and presymptomatic diagnosis of spinal muscular atrophy","volume":"10","author":"J\u0119drzejowska","year":"2020","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2026.e00880_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms12010024","article-title":"Biomarkers in rare disorders: the experience with spinal muscular atrophy","volume":"12","author":"Tiziano","year":"2010","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/acn3.689","article-title":"Novel challenges in spinal muscular atrophy - how to screen and whom to treat?","volume":"6","author":"Saffari","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030075","article-title":"The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment","volume":"10","author":"Smeriglio","year":"2020","journal-title":"J Personalized Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","article-title":"Spectrum of neuropathophysiology in spinal muscular atrophy type I","volume":"74","author":"Harding","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.gde.2013.03.003","article-title":"How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches","volume":"23","author":"Wirth","year":"2013","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00880_bib10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00880_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","article-title":"Onasemnogene abeparvovec: a review in spinal muscular atrophy","volume":"36","author":"Blair","year":"2022","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00880_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00880_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00880_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e00880_bib15","series-title":"Device for quantitative analysis of a drug or metabolite profile","author":"Ramsay","year":"2012"},{"key":"10.1016\/j.neurot.2026.e00880_bib16","series-title":"Apparatus and method for analyzing a metabolite profile","author":"Ramsay","year":"2012"},{"key":"10.1016\/j.neurot.2026.e00880_bib17","first-page":"1","article-title":"Plasma neurofilament light chain as a potential biomarker of presymptomatic spinal muscular atrophy","author":"Jin","year":"2026","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00880_bib18","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1194\/jlr.M037622","article-title":"Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in alzheimer's disease","volume":"54","author":"Fonteh","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.neurot.2026.e00880_bib19","article-title":"EnhancedVolcano: publication-Ready volcano plots with enhanced colouring and labeling","volume":"1.27.0","author":"Blighe K","year":"2025","journal-title":"R package version"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00880_bib20","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties","volume":"33","author":"Conway","year":"2017","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib21","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"key":"10.1016\/j.neurot.2026.e00880_bib22","series-title":"ggplot2: elegant graphics for data analysis","author":"W.H","year":"2016"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1385\/JMN:14:3:123","article-title":"Deacylation and reacylation of neural membrane glycerophospholipids","volume":"14","author":"Farooqui","year":"2000","journal-title":"J Mol Neurosci"},{"issue":"15_supplement","key":"10.1016\/j.neurot.2026.e00880_bib24","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1212\/WNL.96.15_supplement.2248","article-title":"Plasma phosphorylated neurofilament heavy chain (pNF-H) level is associated with future motor function in nusinersen-treated individuals with later-onset spinal muscular atrophy (SMA) (2248)","volume":"96","author":"Farrar","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00880_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00880_bib26","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","article-title":"Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges","volume":"62","author":"Bayoumy","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00880_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12155060","article-title":"Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy","volume":"12","author":"Babi\u0107","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00880_bib28","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1515\/cclm-2023-1119","article-title":"Value of plasma neurofilament light chain for monitoring efficacy in children with later-onset spinal muscular atrophy under nusinersen treatment","volume":"62","author":"Jin","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.neurot.2026.e00880_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1269406","article-title":"Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi","volume":"14","author":"Flotats-Bastardas","year":"2023","journal-title":"Front Neurol"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00880_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206696","article-title":"Cerebrospinal fluid proteomic changes after nusinersen in patients with spinal muscular atrophy","volume":"12","author":"Beaudin","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib31","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1038\/s41598-018-24064-0","article-title":"Essential role of Linx\/Islr2 in the development of the forebrain anterior commissure","volume":"8","author":"Abudureyimu","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00880_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000348","article-title":"Genetic risk of parkinson disease and progression:: an analysis of 13 longitudinal cohorts","volume":"5","author":"Iwaki","year":"2019","journal-title":"Neurol Genet"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00880_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00018-023-04885-7","article-title":"Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study","volume":"80","author":"Faravelli","year":"2023","journal-title":"Cell Mol Life Sci : CM"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-024-05426-6","article-title":"Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy","volume":"81","author":"Panicucci","year":"2024","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00880_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11051254","article-title":"Identification of novel biomarkers of spinal muscular atrophy and therapeutic response by proteomic and metabolomic profiling of human biological fluid samples","volume":"11","author":"Meneri","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00880_bib36","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00880_bib37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"Freigang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1515\/cclm-2016-0275","article-title":"Evaluation and comparison of three assays for molecular detection of spinal muscular atrophy","volume":"55","author":"Li","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00415-025-12909-4","article-title":"Multi-omics profiling in spinal muscular atrophy (SMA): investigating lipid and metabolic alterations through longitudinal CSF analysis of Nusinersen-treated patients","volume":"272","author":"Zandl-Lang","year":"2025","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00880_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00415-025-12909-4","article-title":"Multi-omics profiling in spinal muscular atrophy (SMA): investigating lipid and metabolic alterations through longitudinal CSF analysis of Nusinersen-treated patients","volume":"272","author":"Zandl-Lang","year":"2025","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00880_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/brain\/awae272","article-title":"The systemic complexity of a monogenic disease: the molecular network of spinal muscular atrophy","volume":"148","author":"Tapken","year":"2025","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00880_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14718","article-title":"Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III","volume":"30","author":"Lu","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00880_bib43","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1007\/s10072-025-08267-8","article-title":"Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients","volume":"46","author":"Li","year":"2025","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0887-8994(94)00100-G","article-title":"Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)?","volume":"12","author":"Tein","year":"1995","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00880_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaneurol.2015.0178","article-title":"Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy","volume":"72","author":"Ripolone","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00880_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1194\/jlr.R300016-JLR200","article-title":"Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases","volume":"45","author":"Sun","year":"2004","journal-title":"JLR (J Lipid Res)"},{"key":"10.1016\/j.neurot.2026.e00880_bib47","doi-asserted-by":"crossref","unstructured":"V. Leong, A.N. Fonteh, Chapter 9 - the importance of phospholipases A2 in alzheimer's disease mechanisms, pathology, and potential therapies, in: S. Chakraborti (Ed.), Phospholipases in physiology and pathology, Academic Press2023, pp. 135-151.","DOI":"10.1016\/B978-0-443-21800-2.00022-1"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00880_bib48","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1161\/ATVBAHA.122.317898","article-title":"Lp-PLA2 (Lipoprotein-Associated phospholipase A2) deficiency lowers cholesterol levels and protects against atherosclerosis in rabbits","volume":"43","author":"Chen","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00880_bib49","first-page":"801","article-title":"Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice","volume":"26","author":"Deguise","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00880_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00441-003-0756-7","article-title":"Bohlen und Halbach, Fibroblast growth factors and their receptors in the central nervous system","volume":"313","author":"Reuss","year":"2003","journal-title":"Cell Tissue Res"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00880_bib51","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1007\/s12035-021-02367-0","article-title":"Fibroblast growth factor signalling in the diseased nervous System","volume":"58","author":"Klimaschewski","year":"2021","journal-title":"Mol Neurobiol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:05:41Z","timestamp":1781640341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1878747926000504"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00880","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal multi-omics profiling of spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00880"}}